HRA011753
Title:
Allogeneic T cells with anti-CD19 STAR integrated into TRAC locus induce immune resetting and sustained remission in refractory systemic lupus erythematosus with severe lupus nephritis
Release date:
2025-06-07
Description:
YTS109 is a hypoimmune allogeneic STAR-T cell product engineered via CRISPR/Cas9 to overcome the limitations of autologous CAR-T therapies, including cost, manufacturing complexity, and insertional mutagenesis risk. In patients with refractory systemic lupus erythematosus and lupus nephritis, YTS109 induced immune resetting and significant clinical remission, offering a promising new therapeutic approach.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
systemic lupus erythematosus
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
STAR-T-SLE-LN
Contact person:
Wang Xiaobing
Email:
gale820907@163.com
Description:
YTS109 is a hypoimmune allogeneic STAR-T cell product engineered via CRISPR/Cas9 to overcome the limitations of autologous CAR-T therapies, including cost, manufacturing complexity, and insertional mutagenesis risk. In patients with refractory systemic lupus erythematosus and lupus nephritis, YTS109 induced immune resetting and significant clinical remission, offering a promising new therapeutic approach.
Individuals & samples
Submitter:   Wang Xiaobing / gale820907@163.com
Organization:   Second Affiliated Hospital of Naval Medical University
Submission date:   2025-06-04
Requests:   1